Just would like honest answer from GC, or this tea
Post# of 30013
![Avatar](/images/ProfileImages/51237198_13048_alien.jpg)
Are we to assume that the 1H-14 deadlines will push into 2h-14 now,
so that all catalysts essentially are 2h-14 including uplisting.
Thats how I read it, other than re-printed news from the past.
Some new meat would be nice.
Amarantus 2014 Current Milestones & Catalysts
LymPro
• Pilot clinical performance data ( 1H-14 );
• Retrospective / prognostic 9 year patient record clinical study ( 1H-14 );
• Clinical Performance studies to support CLIA registration ( 1H-14 );
• Commercial Launch as a Laboratory-Developed Test (“LDT”) under CLIA (2H- 2014);
Eltoprazine
• Evaluate best indication for commercial development ( 1H/14 )
• Initiate Phase 2b Clinical Trial ( 1H/14 )
MANF
• Retinitis Pigmentosa: functional genetic mouse model ( 1H-14 )
• Parkinson’s disease: CED delivery data w/Renishaw ( 1H-14 )
• Preliminary systemic toxicology (PK/PD relationship) ( 1H-14 )
• Wolfram Syndrome enablement (Diabetes)
Read More: http://investorshangout.com/post/view?id=1551...z352n8Wdck
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)